Nippon Life Global Investors Americas Inc. boosted its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 97.6% during the 1st quarter, Holdings Channel reports. The firm owned 76,990 shares of the medical instruments supplier’s stock after purchasing an additional 38,020 shares during the quarter. Becton Dickinson and makes up approximately 1.5% of Nippon Life Global Investors Americas Inc.’s portfolio, making the stock its 14th biggest holding. Nippon Life Global Investors Americas Inc.’s holdings in Becton Dickinson and were worth $19,226,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently modified their holdings of the company. IMS Capital Management acquired a new position in Becton Dickinson and during the 3rd quarter valued at approximately $29,000. Oregon Public Employees Retirement Fund boosted its position in Becton Dickinson and by 22,485.4% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 6,545,502 shares during the period. RPG Investment Advisory LLC acquired a new position in Becton Dickinson and during the 1st quarter worth $32,000. Nalls Sherbakoff Group LLC acquired a new position in Becton Dickinson and during the 4th quarter worth $34,000. Finally, Aspire Private Capital LLC acquired a new position in Becton Dickinson and during the 4th quarter worth $39,000. Institutional investors own 84.89% of the company’s stock.
In related news, CEO Vincent A. Forlenza sold 3,123 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total transaction of $796,458.69. Following the completion of the transaction, the chief executive officer now owns 215,372 shares of the company’s stock, valued at approximately $54,926,321.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ribo Alberto Mas sold 4,808 shares of the business’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $255.03, for a total value of $1,226,184.24. Following the transaction, the executive vice president now directly owns 22,476 shares of the company’s stock, valued at approximately $5,732,054.28. The disclosure for this sale can be found here. Insiders have sold a total of 29,684 shares of company stock valued at $7,518,574 in the last three months. 0.12% of the stock is owned by insiders.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.58 by $0.12. Becton Dickinson and had a return on equity of 14.65% and a net margin of 5.69%. The business had revenue of $4.16 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the firm earned $2.48 EPS. The firm’s revenue was up 35.1% compared to the same quarter last year. As a group, analysts expect that Becton Dickinson and Co will post 12.07 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Investors of record on Friday, June 7th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Thursday, June 6th. This represents a $3.08 annualized dividend and a dividend yield of 1.30%. Becton Dickinson and’s dividend payout ratio is presently 27.97%.
A number of research firms have recently commented on BDX. Barclays boosted their price objective on Becton Dickinson and from $260.00 to $266.00 and gave the stock an “equal weight” rating in a research note on Monday, April 15th. Zacks Investment Research downgraded Becton Dickinson and from a “hold” rating to a “sell” rating in a research note on Monday, April 22nd. TheStreet raised Becton Dickinson and from a “c+” rating to an “a” rating in a research note on Tuesday, February 5th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Finally, Piper Jaffray Companies boosted their price objective on Becton Dickinson and to $274.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 5th. Six equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $256.25.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Featured Story: Convertible Shares
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.